"Uridine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ribonucleoside in which RIBOSE is linked to URACIL.
| Descriptor ID |
D014529
|
| MeSH Number(s) |
D03.383.742.680.852 D13.570.685.852 D13.570.800.892
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Uridine".
Below are MeSH descriptors whose meaning is more specific than "Uridine".
This graph shows the total number of publications written about "Uridine" by people in this website by year, and whether "Uridine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uridine" by people in Profiles.
-
Oral decitabine-cedazuridine in acute myeloid leukaemia. Br J Haematol. 2024 Nov; 205(5):1674-1676.
-
Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine. Nat Commun. 2024 Jul 30; 15(1):6421.
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
-
Characterization of SARS2 Nsp15 nuclease activity reveals it's mad about U. Nucleic Acids Res. 2021 09 27; 49(17):10136-10149.
-
Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant. Clin Colorectal Cancer. 2021 09; 20(3):273-278.
-
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683.
-
Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy. Genet Med. 2020 10; 22(10):1598-1605.
-
Real-time comprehensive toxicology testing in the clinical management of accidental pediatric capecitabine ingestion. J Oncol Pharm Pract. 2020 Oct; 26(7):1759-1761.
-
Stable native RIP9 complexes associate with C-to-U RNA editing activity, PPRs, RIPs, OZ1, ORRM1 and ISE2. Plant J. 2019 09; 99(6):1116-1126.